| Good Samaritan Society - Parsons | |
| 709 Leawood Avenue, Parsons, Kansas 67357 | |
| (620) 421-1110 | |
| Name | Good Samaritan Society - Parsons |
|---|---|
| Location | 709 Leawood Avenue, Parsons, Kansas |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 54 |
| Occupancy Rate | 82.59% |
| Medicare ID (CCN) | 175210 |
| Legal Business Name | The Evangelical Lutheran Good Samaritan Society |
| Ownership Type | Non Profit - Corporation |
| NPI Number | 1376533836 |
| Organization Name | THE EVANGELICAL LUTHERAN GOOD SAMARITAN SOCIETY |
| Doing Business As | GOOD SAMARITAN SOCIETY - PARSONS |
| Address | 709 Leawood Dr, Parsons, KS 67357 |
| Phone Number | 620-421-1110 |
News Archive
Zydus Cadila, an innovative global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare products, and Pieris AG, a next generation therapeutic protein R&D company, have entered into an alliance for development and commercialization of multiple novel Anticalin-based protein therapeutics, both companies announced today.
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that the Company has achieved delivery of novel small interfering RNA conjugates to the central nervous system and is planning to advance a pipeline of investigational RNAi therapeutics into clinical development.
Democrats nurtured entitlements, which provided a bedrock of security for Americans. But we never said no to entitlement expansion or benefit increases. We haven't supplied enough discipline, and they are out of control. Conversely, we've ignored the New Frontier investment programs, bragging about them but meting out only subsistence rations. They're now stunted and need higher rations. We have one more chance. The fiscal cliff was designed to force tough choices.
Furiex Pharmaceuticals, Inc. announced today that it has acquired full exclusive license rights to develop and commercialize the compound JNJ-Q2 under its existing development and license agreement with Janssen Pharmaceutica N.V.. Furiex acquired these rights as a result of Janssen's decision not to exercise its option under the agreement that gave Janssen the opportunity to continue development of JNJ-Q2.
A simple method of testing "twilight vision" gives reliable results in identifying people who have decreased visual acuity under low light conditions, according to a study in the May issue of Optometry and Vision Science, official journal of the American Academy of Optometry.
› Verified 8 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Zydus Cadila, an innovative global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare products, and Pieris AG, a next generation therapeutic protein R&D company, have entered into an alliance for development and commercialization of multiple novel Anticalin-based protein therapeutics, both companies announced today.
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that the Company has achieved delivery of novel small interfering RNA conjugates to the central nervous system and is planning to advance a pipeline of investigational RNAi therapeutics into clinical development.
Democrats nurtured entitlements, which provided a bedrock of security for Americans. But we never said no to entitlement expansion or benefit increases. We haven't supplied enough discipline, and they are out of control. Conversely, we've ignored the New Frontier investment programs, bragging about them but meting out only subsistence rations. They're now stunted and need higher rations. We have one more chance. The fiscal cliff was designed to force tough choices.
Furiex Pharmaceuticals, Inc. announced today that it has acquired full exclusive license rights to develop and commercialize the compound JNJ-Q2 under its existing development and license agreement with Janssen Pharmaceutica N.V.. Furiex acquired these rights as a result of Janssen's decision not to exercise its option under the agreement that gave Janssen the opportunity to continue development of JNJ-Q2.
A simple method of testing "twilight vision" gives reliable results in identifying people who have decreased visual acuity under low light conditions, according to a study in the May issue of Optometry and Vision Science, official journal of the American Academy of Optometry.
› Verified 8 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 12.99 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 10.87 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 13.59 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 3.57 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 6.25 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 1.23 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 3.76 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 13.56 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 92.59 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 17.22 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 25.61 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 4.82 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 100 | 95.98 |